| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
IO Biotech, Inc.
$0
+0.02 (+68.42%)
D 28Pipeline Score Overvalued Biotech · Clinical
Market Cap
3.45 M
EPS
-1.34
P/E Ratio
-
Value Trade
3.41
-75.56 %
Week
-84.64 %
1 Month
-92.07 %
3 Month
-90.46 %
6 Month
-99.7 %
5 Year
-99.7 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
33.69 K
52 Week Range
0.03 - 2.79
% held by Insiders
16.12 %
% held by Institutions
40.08 %
Enterprise Value
-9.09 M
Total Shares
72.06 M
Short %
15.48 %
Float Shares
13.91 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-08-11 | Cylembio® (imsapepimut and etimupepimut, adjuvanted) | phase 3 data readout | Phase 3 | — | – | – | – |
2025-08-11 | Cylembio® (imsapepimut and etimupepimut, adjuvanted) | phase 3 data readout | Phase 3 | — | – | – | – |
2025-08-11 | Cylembio® (imsapepimut and etimupepimut, adjuvanted) | phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
D28
Pipeline Score $2M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.7x
rNPV / MCap Top 31%
Micro Cap (rank 645 of 933)
Percentile RankIO Biotech, Inc. faces pipeline headwinds (28/100), with $789M risk-adjusted pipeline value, led by IO102-IO103 in Melanoma (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IO102-IO103 Small molecule | Metastatic Melanoma | Phase 3 | NCT05155254 | 65% | $387M | ACTIVE NOT_RECRUITING | 407 | AVERAGE | C (59) | Sep 1, 2027 | MODERATE_RISK | Aug 28, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IO102-IO103 Breakthrough | metastatic melanoma | Phase 1/2 | 2025-12-15 | median progression free survival: 25.5 months; median overall survival: 60 months; median duration of response: more than 53 months Read More | IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications Read More | |
IO102-IO103 Breakthrough | metastatic melanoma | Phase 1/2 | 2025-12-15 | median progression free survival: 25.5 months; median overall survival: 60 months; median duration of response: more than 53 months Read More | IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications Read More | |
IO102-IO103 Breakthrough | metastatic melanoma | Phase 1/2 | 2025-12-15 | median progression free survival: 25.5 months; median overall survival: 60 months; median duration of response: more than 53 months Read More | IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IOBT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IOBT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How IOBT ranks across every disease it competes inCompetitive Position is a premium feature
See how IOBT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial